The gastrointestinal immune system plays a pivotal role in the host relationship with food antigens, the homeostatic microbiome and enteric pathogens. Here, we describe how to collect and process liver and intestinal samples to efficiently isolate and analyse resident immune cells. Furthermore, we describe a step-by-step methodology showing how to high-dimensionally immunophenotype resident leucocytes using cytometry by time-of-flight, providing a well-characterized antibody platform that allows the identification of every leucocyte subset simultaneously. This protocol also includes instructions to purify and cultivate primary murine hepatocytes, a powerful tool to assess basic cell biology and toxicology assays. Gut and liver samples from the same mouse can be collected, processed and stained in less than 6 hr. This protocol enables the recovery of several populations of purified and viable immune cells from solid and fibrous organs, preventing unwanted loss of adherent cells during isolation.
Introduction
The gastrointestinal immune system (GIS), which includes the gastrointestinal tract, liver and associated lymphoid organs such as mesenteric lymph nodes, appendix (caecal patch in mice) and Peyer's patches, harbours one of the most complex populations of immune cells in our body. 1, 2 Indeed, all leucocyte subsets can be found under homeostatic conditions within the intestines 1, 3 or the liver. 4, 5 These resident immune cells play a crucial role for tissue homeostasis from embryonic phase and throughout adulthood. GIS cells are involved in tissue remodelling and repair, 6 immune tolerance to food antigens 7, 8 and they sustain a healthy relationship with our commensal microbiota. 9 For this, an exquisite network of immune cells organizes an efficient firewall against dissemination of gut-derived bacteria, viruses and other pathogens within circulation. Notably, disruption of gastrointestinal homeostasis due to gut and liver diseases is associated with several infectious and inflammatory diseases, including sepsis, [10] [11] [12] and autoimmune 13, 14 and auto-inflammatory diseases. 13, 15 Therefore, it is becoming increasingly clear that expanding our knowledge on the immunobiology of the GIS may guide future clinical interventions and diagnoses, and also add to the development of more precise immune-based therapies.
The gastrointestinal tract is composed of a unique vascular and parenchymal architecture that comprises a
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diverse array of tissue-resident immune cells to mediate homeostatic functions of the organs. Taking into account that these cells are usually part of an intricate tissue network, their isolation for ex vivo studies can be challenging. Indeed, improper tissue processing will lead to inefficient recovery of leucocyte subtypes, which will not reflect the actual pool of resident cells. Moreover, cells with larger protrusions (i.e. macrophages or dendritic cells) or cells within the connective tissue that are firmly adhered to the extracellular matrix will be inadvertently discarded during the isolation procedure. 16 Hence, reliable and efficient cell isolation procedures specifically designed for solid and fibrous organs are of broad interest.
Efforts to characterize the tissue-resident immune cell populations in the GIS have to date mostly relied on flow cytometry-based analysis, which has proven to be an invaluable tool to identify and assess the role of GIS-resident immune cells in homeostasis and disease pathogenesis. 17, 18 However, traditional flow cytometry has limitations that can make data interpretation difficult, these limitations include: a relatively small number of markers per panel and spectral overlap of fluorescent markers leading to compensation artefacts. These limitations are particularly evident in the characterizations of non-lymphoid cell populations, (monocytes, macrophages, dendritic cells and granulocytes) in the liver and small intestine lamina propria, which harbour numerous unique tissue-resident subsets that require several specific markers to study.
To overcome some of the limitations of flow cytometry, cytometry by time-of-flight (CyTOF), mass cytometry ( Fig. 1) was recently developed and its use has become more widespread. [19] [20] [21] [22] [23] [24] This technique uses a mass spectrometer to characterize single cells labelled with antibodies conjugated to metal isotopes instead of the fluorophores used in traditional flow cytometry. Currently, over 40 isotope-conjugated markers can be analysed in a single panel without the need to compensate different isotope channels. The high-dimensional data that are generated from using this many markers can be analysed straightforwardly using widely available algorithms on CYTOBANK, these include viSNE, 25 CITRUS 26 and SPADE. 27 One of the drawbacks of CyTOF is that the sample must comprise a purified cell population because the cells are vaporized during the run and gating for cells is based on DNA content, which will be compromised by samples with a high density of debris. This is an important consideration for the study of immune cells from the GIS, where the digestion of tissues such as the intestine and liver leads to loss of cell viability and generates a large amount of residual debris.
Here, we describe a robust and simple protocol for the isolation, staining and CyTOF analysis of purified and viable leucocytes from the intestinal lamina propria and mesenteric limph nodes (Box 2 and 3, respectively) and the liver that generates high-quality and reproducible high-dimensional immunophenotyping data of the GIS. Additionally, using the same protocol, we also describe the procedures to isolate leucocytes from the mesenteric lymph nodes, and how to cultivate primary mouse hepatocytes. This may be of interest to groups studying liver biology and toxicology.
The integrated protocol, encompassing cell isolation to analysis of gastrointestinal immune cells, described here will expedite discoveries in uncovering the role of the GIS in health and disease. Indeed, high-dimensional analysis can offer a more detailed characterization of the dynamic changes in resident cell populations during the disease courses of models of chronic inflammation (e.g. inflammatory bowel disease, hepatitis) or gastrointestinal cancers, and after perturbation to GIS homeostasis (e.g. changes in diet, microbiome). For example, we recently used viSNE to characterize the distinct temporal changes of novel myeloid cell clusters during the repopulation and seeding of liver phagocytes after depletion. 23 Another emerging application of CyTOF analysis is the discovery of novel single cell-based biomarkers, where the high-dimensional nature of CyTOF data permits more rapid screening of targets than would be possible using traditional flow cytometry. 21 Taking into account that this protocol deals with challenging solid and fibrous tissues, and the immunophenotyping methodology proposed here covers the majority of the leucocyte subsets, minimal modifications would allow the processing and analysis of different organs other than the gastrointestinal tract, which may include brain, lung, spleen and others.
One of the current limitations of CyTOF is the low sample acquisition rate of the mass cytometer (200-600 events per second) compared with a traditional flow cytometer (i.e. BD FACS Aria; BD, Franklin Lakes, NJ; up to 20 000 events per second). To circumvent this low acquisition rate, individual samples can be bar-coded and pooled together for a single run. However, the low acquisition rate will still make it difficult to analyse very rare populations, as it would take 20-100 times longer than flow cytometry to collect enough events for proper statistical testing. One solution for analysing very rare populations by mass cytometry is to first enrich for these populations using bead or flow-sorting-based techniques before staining and running on the mass cytometer.
Materials and methods

Reagents
Common use of reagents. . Cells are labelled with a panel of heavy-metalconjugated probes using methods very similar to flow cytometry staining protocols. The single-cell suspension is introduced into the nebulizer where it is aerosolized (step 1). It is critical to remove as much water as possible from the sample so that it can be efficiently ionized in the plasma. This is achieved first by aerosolizing the sample in the nebulizer followed by delivery to the plasma through the heated spray chamber. The single-cell aerosol droplets that exit the spray chamber are transmitted to the inductively coupled plasma (ICP) source where they are vaporized, atomized and ionized in the plasma for subsequent mass analysis (step 2). This results in the formation of an ion cloud containing the ions derived from metal-conjugated probes, endogenous cell components and argon. The ion cloud then passes through the plasma-vacuum interface. The purpose of the vacuum interface is to efficiently transport ions from the plasma at atmospheric pressure to the chambers that house the ion optics at less than 10 À3 Torr (step 3). Mass cytometers use a three-cone interface to transport the ion beam into a low-pressure vacuum: sampler, skimmer and reducer. Low-mass ions, non-ionized particles and photons are removed in the high-pass ion optics, resulting in a cloud of ions enriched for the probe isotopes. The ion clouds that exit the high-pass ion optic consist of a mixture of high-molecular-weight probes in a randomly distributed array. These ions are sent to the TOF mass analyser, which separates the ions on the basis of their mass-to-charge ratio (step 4). The ion clouds, now enriched for high mass ions, enter through the entrance slit into the accelerator chamber of the TOF analyser. At 13-microsecond intervals, or pushes (frequency of 76Á8 kHz), a pulse is applied to the push-out plate, accelerating the accumulated packet of ions orthogonally toward the reflector, which redirects the ions toward the detector. The electric fields in the accelerator and reflector are configured to focus ions into tight time-resolved bands regardless of initial position or energy. Each packet of ions resolves into a series of bands, with the lightest probes reaching the detector first and each successively heavier mass reaching the detector at a later time. Each time-resolved band of ions of mass M is separated from its M AE 1 neighbour by 20-25 ns. After the first packet of ions is pushed out and detected, a second pulse pushes out the next packet of ions for detection and the cycle repeats until data acquisition is complete. Data for each 13-microsecond push are digitized sequentially and integrated to obtain ion counts for the channels selected for analysis (steps 5 and 6). The resulting record is processed according to cell event selection criteria set by the user. These criteria include a minimum signal threshold and a range for event duration consistent with single-cell events. As a result, the data acquired contain the integrated number of total ion counts for each selected analyte on a per-cell basis. These data are saved as text (.txt) and flow cytometry standard (.fcs) 3.0 format for data analysis in compatible software programs (step 7 Solutions for liver cell isolation -non-parenchymal cells. RPMI-1640 medium: In a beaker, dilute the contents of a sachet of RPMI-1640 in 800 ml of distilled water. Add 2Á2 g of sodium bicarbonate and 10 ml of penicillinstreptomycin (100 9). Complete up to a final volume of 1000 ml, keeping the solution under constant stirring with a magnetic stirrer. Digestion solution 1 -liver non-parenchymal cell isolation: Dilute 10 mg of collagenase (1 mg/ml) in 9 ml of RPMI-1640 medium supplemented with 1 ml of FBS (10% vol/vol).
Solutions for liver cell isolation -hepatocytes. Williams' medium E: In a beaker, dilute the contents of a sachet of RPMI-1640 in 800 ml of distilled water. Add 2Á2 g of sodium bicarbonate and 10 ml (1/100 vol/vol) of Pen strep (100 9). Complete for a final volume of 1000 ml keeping the solution under constant stirring with a magnetic stirrer. Measure the pH, filter into sterile receptacle and store at 4°.
Stock solutions to prepare Hanks' A and B (for hepatocytes isolation):
1Á9 g of potassium chloride (KCl -50 mM), 0Á27 g of potassium dihydrogen phosphate (KH 2 PO 4 -4 mM) and 0Á14 g of disodium phosphate (Na 2 HPO 4 -2 mM) in 400 ml of distilled water keeping the solution under constant stirring with a magnetic stirrer. Complete for a final volume of 500 ml, filter and store at 4°.
Solution 2: In a beaker, dilute 26Á25 g of sodium bicarbonate (NaHCO 3 -625 mM) in 400 ml of distilled water keeping the solution under constant stirring with a magnetic stirrer. Complete for a final volume of 500 ml, filter and store at 4°.
Solution 3: In a beaker, dilute 1Á23 g of magnesium sulphate heptahydrate (MgSO 4 Á7H 2 O -10 mM), 1Á27 g of magnesium chloride hexahydrate (MgCl 2 Á6H 2 O -12Á5 mM) and 5Á51 g of calcium chloride dihydrate (CaCl 2 Á2H 2 O -75 mM) in 400 ml of distilled water keeping the solution under constant stirring with a magnetic stirrer. Complete to a final volume of 500 ml, filter and store at 4°.
Hanks' A solution: In a beaker, dilute 0Á5 g of D-glucose (0Á1% wt/vol), 0Á095 g of EGTA (0Á5 mM), 50 ml of the stock solution 1, 50 ml of the stock solution 2 and 10 ml of penicillin-streptomycin (100 9) in 400 ml of distilled water keeping the solution under constant stirring with a magnetic stirrer. Complete for a final volume of 500 ml, set pH to 7-7Á4, filter and store at 4°.
Hanks' B solution: In a beaker, dilute 0Á5 g of D-glucose (0Á1% wt/vol), 50 ml of the stock solution 1, 20 ml of the stock solution 2, 20 ml of the stock solution 3 and 10 ml of penicillin-streptomycin (100 9) in 400 ml of distilled water keeping the solution under constant stirring with a magnetic stirrer. Complete for a final volume of 500 ml, set pH to 7-7Á4, filter and store at 4°.
Digestion solution 2 -hepatocyte isolation: Dissolve 20 mg of collagenase in 25 ml of Hanks' B to obtains a 0Á8 mg/ml collagenase solution.
Sodium hypochlorite solution: Dilute 10 ml of sodium hypochlorite in 90 ml of distilled water.
Solutions for lamina propria cell isolation. EDTA stock solution: Dissolve 116Á9 g of EDTA in H 2 O to obtain a 0Á5 M stock solution. Stir vigorously on a magnetic stirrer. Adjust the pH to 8Á0 with NaOH. Dispense into aliquots and sterilize by autoclaving.
Lamina propria buffer A: Mix 25 ml of FBS and 12Á5 ml of HEPES (1 M) in 462Á5 ml of Hanks' balanced salt solution (HBSS). Sterilize the solution by filtration using a 0Á22-lm syringe filter, and store it for up to 1 month at 4°.
Lamina propria buffer B: Mix 2 ml of EDTA stock solution (0Á5 M) and 12Á5 ml of HEPES (1 M) in 485Á5 ml of HBSS. Sterilize the solution by filtration using a 0Á22-lm syringe filter, and store it for up to 1 month at 4°.
Lamina propria buffer C: Mix 5 ml of EDTA stock solution (0Á5 M), 50 ml of FBS and 0Á5 ml of HEPES (1 M) in 437Á5 ml HBSS and then dissolve 0Á77 g of dithiothreitol to obtain a 1 mM solution. Sterilize the solution by DNAse stock solution: Dissolve 20 mg of DNAse in 10 ml of sterile saline solution, 0Á9% (wt/vol) to obtain a 2 mg/ml (4000 U/ml) stock solution. Store the solution in 1 ml aliquots at À20°for up to 1 month.
MACS buffer: Dissolve 50 g of BSA (0Á5% -wt/vol) in 100 ml of PBS 1 9 and store up to 1 week at 4°.
Solutions for CyTOF staining. Cell staining buffer -CSB: Dissolve 2Á5 g of BSA and 100 mg of sodium azide in 500 ml low-barium PBS. Store in a Nalgene polypropylene bottle that has never been washed with detergent. Prepare up to 1 month in advance and store at 4°.
Intercalator solution: MaxPar Intercalator-Ir 500 lM 1 : 4000 dilution in MaxPar Fix and Perm Buffer.
Procedures for hepatocyte culture. The culture of hepatocytes (see hepatocutes isolatin in BOX 1) is performed in 6-well and 24-well plates with or without cover slip, depending on the purpose of the experiment.
Preparation of the cover slips: Using a small forceps, wash each cover slip individually, according to the following sequence: distilled water (five times), absolute ethanol (five times), hydrochloric acid (HCl, 1 M) for 1 hr, distilled water (five times), absolute ethanol (five times). Place it to dry in the laminar flow on a sterile filter paper for approximately 30 min, keeping the UV light on. Subsequently, turn the cover slips so that they stay under UV light for over 30 min. Place one coverslip inside each well.
Preparation of the plates: 1 day before the hepatocytes isolation experiment, treat the plates and the cover slips with type I collagen (see Reagent set-up) to enhance cell adhesion. Prepare the solution of type I collagen at a concentration of 5 lg/cm 2 and pipette it into the wells. In wells with cover slip, pipette slowly and carefully, so that the solution can form a big drop just on the surface of the cover slip without draining to the bottom of the wells. Let it dry overnight in laminar flow under UV light. The plates and cover slips treated with type I collagen can be sealed and stored at 4°for a week. Before use, hydrate collagen with Williams' E medium for 30 min. Remove medium before adding the required amount of cell suspension. Procedure Cannulation of the portal vein timing:~1 hr.
1 Clean the perfusion catheter with sodium hypochlorite solution (see Reagent set-up) for 5 min at fast flow. 2 Wash the perfusion catheter with distilled water for 10 min at fast flow. 3 Calibrate the water bath to 37°to preheat the solutions before perfusion. The liver should be perfused with Hanks' A and Hanks' B for hepatocyte isolation, and with PBS 1 9 for hepatic non-parenchymal cell isolation. 4 Calibrate the perfusion pump to medium flow of 12Á5 ml/min. 5 Anaesthetize the mouse by intraperitoneal injection (see Reagent set-up for dose). Wait about 10 min until mouse is under deep anaesthesia. 6 Position the mouse on a surgical stage with the abdomen facing up, taping the animal by the limbs (Fig. 2a) . 7 Apply 70% ethanol on the chest and abdominal skin of the mouse. This will avoid small pieces of fur entering the peritoneal cavity. Perform the midline incision in the abdomen from the pubis to the xiphoid process (Fig. 2b) .
8 Dissociate the abdominal musculature from the skin to allow the visualization of blood vessels and to prevent disruption and possible bleeding. Perform lateral incisions in the skin and, subsequently, in the abdominal muscles along the costal margin to the mid axillary line (Fig. 2c ). 9 Slide abdominal viscera to the right side using a cotton swab (Fig. 2d) . 10 Stabilize abdominal viscera with self-closing forceps to visualize the portal vein (Fig. 2e) . 11 Locate the hepatic portal vein (white arrow), and move the forceps and the organs until the portal vein remains straight to be cannulated (Fig. 2f ). 12 Using a Mayo-Hegar needle holder with a 20 mm needle and 5-0-nylon filament, trespass the suture under (dorsally) the hepatic portal vein (Fig. 2g,h ). 13 Make a loose knot with the nylon filament around the hepatic portal vein without tying the blood vessel (Fig. 2i) .
Peyer′s patches 14 Insert the catheter inside the loose knot made with the suture thread so that, after cannulating the hepatic portal vein the knot will hold the catheter and keep it immobilized during perfusion (Fig. 2j) . 15 Carefully and with the bevel of the catheter facing up, cannulate the hepatic portal vein at the middle portion of its exposed part. To do this, position the catheter parallel to the hepatic portal vein and with a small angle (~5°) insert the needle approximately 5 mm into the vein. 16 After cannulating, require the help of a second person to tight the knot around the portal vein and the catheter (Fig. 2k) . Keep the catheter immobilized until the knot is tight. Release the catheter with extreme caution to prevent rupture of the blood vessel or untie the knot. 17 Start the perfusion for 1-2 seconds to check whether the vein was properly cannulated and then stop perfusion, the liver should change its colour to pale/beige and no leakage should occur. 18 Cut inferior vena cava using a scissor to release the blood and start the perfusion immediately (Fig. 2l) . 19 The liver changes rapidly to its original colour after the blood is washed by the perfusion solution (Fig. 2m,n) . 20 Wait until the perfusion is over and then carefully remove the liver. For liver non-parenchymal cells isolation follow next steps. However, this protocol can also be used for hepatocyte isolation (Box 1).
Isolation of liver non-parenchymal cells timing:~1 hr 30 min.
21 After cannulation (Fig. 2) , perfuse the liver with 50 ml of PBS 1 9 (see Reagent set-up) previously warmed at 37°. Keep the solution in the water bath during perfusion. 22 Carefully remove the liver from the peritoneal cavity and wash it in a Petri dish containing PBS once (Fig. 3a) . This will remove blood and clots from liver surface. 23 Transfer to another Petri dish with 3 ml of the digestion solution 1 (see Reagent set-up) for hepatic nonparenchymal cell isolation (Fig. 3b) . 24 Mince the liver into small pieces (Fig. 3c,d ) using scissors. 25 Transfer the minced liver to a 50-ml tube. Collect all the small liver pieces with the rest of digestion solution (~7 ml). 26 Incubate for 30 min at 37°under constant stirring. 27 Filter the homogenate (Fig. 2e) using a 70 lm cell strainer and transfer the filtrate to a 50-ml tube. 28 Complete the tube with cold RPMI medium 10% FBS (vol/vol) to a final volume of 50 ml. 29 Centrifuge at 4°for 5 min at 300 g. This step will retrieve all cells in suspension. 30 Discard the supernatant and resuspend the pellet in 15 ml of cold RPMI medium 10% FBS (vol/vol).
31 Transfer the samples to 15-ml tubes and centrifuge at 4°for 3 min at 60 g. This step will eliminate hepatocytes and possible lumps. 32 Collect the supernatant and transfer it to a 15-ml tube. Centrifuge at 4°for 3 min at 60 g. This step will eliminate hepatocytes. 33 Collect the supernatant; transfer it to a 15 ml tube. Centrifuge at 4°for 5 min at 300 g. This step will recover all the cells in suspension, with the exception of hepatocytes. 34 Discard supernatant. 35 Resuspend the pellet in 200 ll of cold RPMI medium 10% FBS (vol/vol). Count the cells (Boxes 1-3) .
Procedures for CyTOF analysis timing:~3-7 hr. Cell-surface CyTOF staining protocol:
1 Prepare single cell suspensions. In general, try to start with 1Á5 9 10 6 to 3 9 10 6 cells in 100 ll. Mouse liver (in 5 ml complete Media) used 100-200 ll suspension; mouse lamina propria (in 1 ml complete media) used 100-200 ll. spread its contents on the Petri dish. Repeat this until there are no large pieces left. 6 Use a previously autoclaved mesh to filter all supernatant from the Petri dish. Use a sterile beaker to collect all supernatant. Gently squeeze the mesh against the beaker wall to help with filtration process. 7 Transfer the filtrate to a 50-ml tube and complete to a final volume of 50 ml with cold William's E medium supplemented with 10% FBS (vol/vol). Critical: Use the medium to wash the Petri dish before filtration and the beaker after filtration. 8 Centrifuge the tube at 60 g for 3 min at 4°. 9 Discard the supernatant and resuspend the pellet in 50 ml cold William's E medium supplemented with 10% FBS. 10 Centrifuge the tube at 60 g for 3 min at 4°. 11 Remove the supernatant and resuspend the pellet in 10 ml of cold William's E medium supplemented with 10% FBS (vol/vol). 12 Mix 10 ll of cells with 10 ll of Trypan Blue and count the cells in a Neubauer chamber (see Reagent set-up). 13 Add the appropriate volume of cells in each well and complete to 2 ml with William's E medium supplemented with 10% FBS (vol/vol). 14 Incubate the cells at 37°with 5% CO 2 for 2 hr to initial adherence. Critical: Cells will remain viable for 6-8 hr (Fig. B1) . Table S1 and S2) were coupled to selected lanthanide metals using the MaxPar ing up, trapping the animal by the limbs using masking tape. 2 Apply 70% ethanol on the skin of chest and abdomen to prevent hair from contaminating the surgery. Perform a midline incision in the abdomen from the pubis to the xiphoid process (Fig. 4a) . 3 Dissociate the abdominal musculature from the skin to allow the visualization of blood vessels and to prevent disruption and possible bleeding. Perform lateral incisions in the skin and, subsequently, in the abdominal muscles along the costal margin to the mid axillary line (Fig. 4b) . 4 Slide the abdominal viscera to the right side with the aid of a cotton swab (Fig. 4c ). 5 Localize and remove mesenteric lymph nodes by finding the caecum localization (if desired) (Fig. 4c,d ). 6 Carefully remove fat tissue from the mesenteric lymph node. 7 Place mesenteric lymph nodes on six-well plates containing 70-lm cell strainers and filled with 7 ml of complete media. The media will allow the organ to be constantly bathed, which may result in better cell survival. 8 Mash mesenteric lymph nodes using a 1-ml syringe plunger. 9 Remove the cell strainers and transfer the media containing single cell suspension to a 15-ml Falcon tube. 10 Centrifuge at 400 g for 5 min at 4°. 11 Discard the supernatant and resuspend the pellet with 500 ll of complete medium. Analysis of CyTOF data using cytobank:
24 Import normalized data .fcs files for liver and lamina propria samples into a new experiment file in CYTO-BANK. 25 Gating Strategy: first, exclude normalization beads (Fig. 6a) , then gate samples on DNA1 and DNA2 double-positive cells to exclude debris and select for cells with appropriate DNA content levels (Fig. 6b) . From the DNA1/2 double-positive gate, gate live immune cells as Cisplatin-negative (195P_Viability yaxis, Fig. 6a ) and CD45-positive (165Ho_CD45 xaxis, Fig. 6c ). Myeloid cells were gated on CD45 + CD3 À CD19 À cells (Fig. 7d) .
26 ViSNE Analysis: analyse gated CD45 + (Fig. 6d,e ) live cells and CD45 + CD3 À CD19 À myeloid cells (Fig. 7e,f) from the liver and lamina propria using the viSNE algorithm in CYTOBANK. Analyse a minimum of 10 000 cells for liver and lamina propria control samples using every marker in the panel for clustering (se Supplementary materials, Tables S1 and S2, for the panels used for the liver and lamina propria). 27 After viSNE analysis, manually define clusters of different cell populations in tSNE1 and tSNE2 dot plots for total CD45 + live cells (Fig. 6d ,e) and CD45 + CD3 À CD19 À myeloid cells (Fig. 7e,f ) from lamina propria and liver samples according to surface marker expression. Assign demarcating colours to each population using overlaid visualization in the CYTOBANK. See Fig. 7 (e,f) for detailed marker expression levels of myeloid subsets in the liver and lamina propria.
Anticipated results (Results and discussion)
The number of cells recovered during this protocol will vary according to the mouse strain, age, gender, and mainly due to experimental model. For example, models for inflammatory diseases usually allow for a higher number of leucocytes. However, under certain conditions (i.e. irradiation, chemical ablation or immunosuppression protocols), mouse leucocyte populations can be dramatically reduced throughout the body. Also, any experimental conditions that induce liver injury (drugs, chemicals, infections, hepatectomy) will decrease the number of viable hepatocytes recovered using this protocol. Under these circumstances, polling samples to achieve sufficient cell density to further staining and analysis may be necessary. Under baseline conditions, an adult mouse (8-12 weeks old, weighing around 20-25 g) yields up to 1 9 10 7 to 5 9 10 7 liver non-parenchymal cells, 1 9 10 7 to 3 9 10 7 hepatocytes, 5 9 10 5 to 10 9 10 5 lamina propria leucocytes and 1 9 10 7 to 2 9 10 7 mesenteric lymph node cells (pool of four lymph nodes). Cell viability after these procedures is usually > 90%. Regarding the identification and immunophenotyping of leucocyte populations, different antibody panels will allow for a high variable number of cell clusters. In this protocol, and based on previous studies, 24, 28 we could identify 20 populations of leucocytes within the liver and lamina propria (Fig. 6) . Further gating on myeloid cells (CD45 + CD3 À CD19 À events) revealed at least 10 different populations in each organ (Fig. 7) . It is worth mentioning that the proposed protocol might be applied not only in a plethora of immune cell characterization under homeostasis, 22, 24 but also during inflammatory processes. 23, 29 In fact, using the same isolation protocol and CyTOF analysis, we recently showed that during massive liver macrophage depletion by clodronate injection (CLL), an overt inflammatory response was observed. Using a multiplexed cytokine array, we demonstrated that several different cytokines, including MIG, interleukin-9, CXCL1, and others were significantly increased after macrophage depletion. Concomitantly, CyTOF analysis revealed that 2 days after CLL injection, all the clusters defined as liver macrophages and dendritic cells were significantly reduced. Interestingly, CyTOF was also useful to monitor their replenishment dynamics over time.
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